Vistin Pharma is strongly committed to maintaining an open dialogue with our shareholders, potential investors, analysts, investment banks and the financial markets.

Our goal is for the share price to reflect the underlying value of the company by providing all price-relevant information to the market.
Last updated 29.03 2022 11:00
Nok 16,80
Since open-0,30 (-1.70%)
Since previous close +0,44 (+2.60%)

Quick links

Reasons to invest
Corporate governance
Share information
Calendar

8 reasons for investing in Vistin Pharma ASA.

Leading Producer
Amongst Top 5 producers of metformin HCl globally
High Quality Reputation
Leading reputation as producer of high quality APIs with strong track record of customer delivery
Attractive Market Dynamics
Established position in growing metformin market
Diverse Client Portfolio
Established client base comprising mix of Big Pharma and leading generics players
Sustained Revenue Growth
Strong growth profile with double digit revenue growth in the last 5 years
Advanced Manufacturing Facilities
State of the art and dedicated manufacturing facility with potential for further expansion
Strong Leadership
Experienced management team with a strong track record
A Front-runner
Leading the ESG culture in the industry

Quarterly Results

2020

DOWNLOAD
Q2
ReportPresentation

2021

Q2
ReportPresentation

2022

Q2
ReportPresentation
Q1
ReportPresentation

Annual Reports

DOWNLOAD
Vistin Pharma ASA Annual Report 2021 (PDF)
Vistin Pharma ASA Annual Report 2020 (PDF)
Vistin Pharma ASA Annual Report 2019 (PDF)
Vistin Pharma ASA Annual Report 2018 (PDF)
Vistin Pharma ASA Annual Report 2017 (PDF)
Vistin Pharma ASA Annual Report 2016 (PDF)
Vistin Pharma ASA Annual Report 2015 (PDF)

Other downloads

DOWNLOAD

Investor calendar

27.4.22
Quarterly Report Q1 - 2022
27.4.22
Annual Report 2021
19.5.22
Annual General Meeting
19.8.22
Q2 and Half-yearly Report
26.10.22
Quarterly Report Q3 - 2022

Main shareholders

NAME

Per 31 December 2022

SHAREHOLDING

% SHARE

1
INTERTRADE SHIPPING AS
12575000
28,4 %
2
HOLMEN SPESIALFOND
3 520 243
7,9 %
3
PACTUM AS
3 519 733
7,9 %
4
MP PENSJON PK
1 719 848
3,9 %
5
FERNCLIFF LISTED DAI AS*
784 280
1,8 %
6
AUGUST RINGVOLD AGENTUR AS
750 315
1,7 %
7
STORKLEIVEN AS
750 000
1,7 %
8
LUCELLUM AS
711 322
1,6 %
9
DNB BANK ASA
641 955
1,4 %
10
MIKLA INVEST AS
620 874
1,4 %
11
IVAR LØGES STIFTELSE
560 000
1,3 %
12
TOM RAGNAR PRESTEGÅRD STAAVIE
512 324
1,2 %
13
CORTEX AS
508 989
1,1 %
14
HENRIK MIDTTUN HAAVIE
505 115
1,1 %
16
WEM INVEST AS
500 000
1,1 %
17
SANDEN EQUITY AS
468 947
1,1 %
18
DYVI INVEST AS
455 500
1,0 %
19
DELTA AS
400 000
0,9 %
20
GINKO AS
350 000
0,8 %
21
ØYSTEIN STRAY SPETALEN
323 650
0,7 %
Total 20 largest shareholders
30 178 095
68,05%
Other shareholders
14 166 497
31,95%
Total number of shares
44 344 592
100%
* Board members of Vistin Pharma, or companies controlled by Board members
Vistin Pharma - Oslo Stock Exchange

Contact

Alexander Karlsen
CFO
Vistin Pharma ASA
+47 970 53 621alexander.karlsen@vistin.com
Alexander Karlsen

Vistin Pharma AS

Østensjøveien 27, NO-0661 Oslo
P.O. Box 6735 Etterstad, NO-0609 Oslo

Social

Linkedin
Copyright 2022 Vistin Pharma AS
Privacy
Designed by Skarpsinn
About UsHistoryVision and ValuePeopleCareerSales
SustainabilityBalance by VistinHealthy environmentPeople in focusClean operations
ProductsProducts and productionExpansion projectTechnologySustainabilityQuality
InvestorsReasons to investReportsCalendarCorporate governanceShare informationAnnouncements
ContactContact personsHeadquarterManufacturing siteGeneral Inquiry
About us
Sustainability
Products
Investors
Contact